GENEVA (AP) — Swiss drug maker Roche Holding AG has ended development of a cholesterol drug that it had hoped could achieve blockbuster status.

Basel-based Roche announced Monday it is pulling the plug on dalcetrapib, which was in late-stage trials to study if it could increase so-called "good" cholesterol.

The company said in a statement the decision was based on the recommendation of its independent data and safety monitoring board.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.